Abbisko Cayman (HKG:2256) plans to spend up to HK$200 million to buy back its shares on-market, a Monday bourse filing said.
The drugmaker was authorized to repurchase a maximum of 70,219,935 shares, representing up to 10% of its issued shares as of June 18, 2024.
The buyback will be financed through the company's financial resources.
The oncology therapies developer also plans to grant its board a new repurchase mandate at its upcoming 2025 annual general meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.